Former Seagen CEO Siegall Takes Helm At New Biotech Morphimmune
A Novel Targeted Oncology Platform
Siegall is moving on after an unhappy exit from Seagen with a new role at another company with a novel targeted oncology platform.
You may also be interested in...
Pfizer expects its acquisition of Seagen to result in $10bn in new revenue by 2030 as the big pharma applies its resources to the target company’s pioneering antibody-drug conjugate technology.
Endocyte paid just $12m upfront a year ago for a potential first-in-class investigational radioligand therapy for prostate cancer. Novartis is buying Endocyte for a whopping $2.1bn., highlighting the company's emphasis on building in radiopharmaceuticals.
The venture capital firm is putting $210m into NSCLC trials for the antibody drug conjugate – with an opportunity in patients who fail on first line immunotherapy the most likely target.